News | July 30, 2008

Hologic 3Q08 Revenues Rise 124 Percent

July 31, 2008 – Hologic Inc. disclosed its third quarter fiscal 2008 operating results, reporting it reined in revenues totaling $429.5 million, a 124 percent increase compared to revenues of $191.5 million in the third quarter of fiscal 2007.

The surge in revenues was primarily attributable to the inclusion of approximately $191.5 million of revenues from the new product lines acquired in the merger with Cytyc Corporation on October 22, 2007.

For the third quarter of fiscal 2008, Hologic reported net income of $61.4 million, or $0.24 per diluted share, compared with net income of $24.7 million, or $0.22 per diluted share, in the third quarter of fiscal 2007. Included in the third quarter of fiscal 2008 results were charges relating to the Cytyc merger of $25.1 million attributable to the amortization of intangibles and a restructuring charge of $6.4 million in connection with the resignation of the Company’s Executive Chairman in May 2008. Earnings per share information for 2007 have been restated to reflect the Company's 2-for-1 stock split effected on April 2, 2008.

The Company’s non-GAAP adjusted net income for the third quarter of fiscal 2008 increased 209 percent to $84.9 million compared to the Company’s non-GAAP adjusted net income of $27.5 million in the third quarter of fiscal 2007. The Company’s fiscal 2008 third quarter non-GAAP adjusted net income excludes a $30.6 million charge to operating expenses to amortize the intangible assets acquired from Cytyc, AEG, BioLucent, Fischer, R2 and Suros and the $6.4 million restructuring charge.

Non-GAAP adjusted net income and non-GAAP adjusted EPS are non-GAAP financial measures. A reconciliation of adjusted net income and adjusted EPS to the Company’s net income (loss) and EPS for the third quarter and first nine months of fiscal 2008 and 2007 is set forth in the supplemental disclosure schedule attached to this press release. When analyzing the Company’s operating performance, investors should not consider these non-GAAP measures as a substitute for net income and EPS prepared in accordance with GAAP.

During the third quarter, Hologic recognized as revenue the sale of 429 Selenia full-field digital mammography systems. At June 28, 2008, the Company’s backlog for orders of Selenia systems was 501 systems, including ten orders for Selenia Dimensions tomosynthesis systems for international markets, and total backlog for all products was $378 million.

For more information: www.hologic.com

Related Content

Videos | Breast Imaging | April 18, 2019
In a keynote lecture at the Society of Breast Imaging (SBI)/American College of Radiology (ACR) 2019 Symposium, ...
Fatty tissue and breast density may be considered in the context of many factors that affect the occurrence and detection of breast cancer

Fatty tissue and breast density may be considered in the context of many factors that affect the occurrence and detection of breast cancer. Permission to publish provided by DenseBreast-info.org

Feature | Breast Imaging | April 18, 2019 | By Greg Freiherr
When planning a screening program to detect the early signs of breast cancer, age is a major consideration.
compressed breast during mammography.
360 Photos | 360 View Photos | April 16, 2019
A 360 view of a simulated breast compression for a...
iCAD Highlighting ProFound AI for Tomosynthesis at 2019 SBI Annual Symposium
News | Computer-Aided Detection Software | April 04, 2019
iCAD announced it will present its latest artificial intelligence (AI) software solution for digital breast...
Ikonopedia Introduces Automated Combined Reporting Package at SBI
News | Mammography Reporting Software | April 04, 2019
Ikonopedia will introduce its new Automated Combined Reporting package at the 2019 Society of Breast Imaging/American...
Konica Minolta Highlights New Exa Mammo Features at SBI/ACR Breast Imaging Symposium
News | Breast Imaging | April 03, 2019
Konica Minolta Healthcare Americas Inc. will highlight new features of Exa Mammo, a picture archiving and communication...
A smart algorithm developed by iCAD

A smart algorithm developed by iCAD outlines and scores a suspicious lesion seen in an image created using digital breast tomography. Displayed is the probability calculated by the algorithm that the outlined area includes a cancerous lesion. Image courtesy of Emily Conant, M.D.

Feature | Artificial Intelligence | April 03, 2019 | Greg Freiherr
  Editor's Note: This article was updated following the SBI symposium.  
Lunit Showcases AI Solution for Breast Cancer at SBI 2019
News | Artificial Intelligence | April 02, 2019
Medical artificial intelligence (AI) startup Lunit announced its attendance at the Society of Breast Imaging (SBI) 2019...